Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chun‐Pu Chu, Holly Janes, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Haiyu Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Haiyan Chen, Isabel Reeder, Lindsay N. Carpp, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros A. Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Thomas Jones, Rubén O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, On behalf of the United States Government (usg) Covid-19 Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (cove) Team, USG/CoVPN Biostatistics TeamNature Communications 2024 · DOI

Abstract

In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS-CoV-2 Omicron era, Omicron subvariants with varying degrees of immune escape now dominate, seropositivity rates are high, and booster doses are administered, raising questions on whether and how these developments affect the bAb and nAb correlates. To address these questions, we assess post-boost BA.1 Spike-specific bAbs and nAbs as CoRs and as correlates of booster efficacy in COVE. For naive individuals, bAbs and nAbs inversely correlate with Omicron COVID-19: hazard ratios (HR) per 10-fold marker increase (95% confidence interval) are 0.16 (0.03, 0.79) and 0.31 (0.10, 0.96), respectively. In non-naive individuals the analogous results are similar: 0.15 (0.04, 0.63) and 0.28 (0.07, 1.08). For naive individuals, three vs two-dose booster efficacy correlates with predicted nAb titer at exposure, with estimates -8% (-126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), at 56, 251, and 891 Arbitrary Units/ml. These results support the continued use of antibody as a surrogate endpoint.

Introduction

As the COVID-19 pandemic evolved, the emergence of the Omicron variant and the widespread prevalence of "hybrid immunity"—immunity derived from both vaccination and prior infection—challenged established immune correlates. This study, utilizing data from the mRNA-1273 (Moderna) COVE trial, investigates whether antibody levels measured after a third dose remain reliable predictors of protection against the Omicron BA.1 variant.

Methods

The researchers conducted a case-control study within the Phase 3 COVE trial (NCT04470427), focusing on a cohort of 15,713 participants who received a 50 $\mu$g third dose of mRNA-1273. BA.1-specific binding antibodies (bAbs) and neutralizing antibodies (nAbs) were measured at the time of the boost (BD1) and 28 days later (BD29). The study employed Cox proportional hazards models to calculate Hazard Ratios (HR) and used mathematical modeling to estimate antibody levels at the time of exposure. Machine learning ensembles were also used to identify the best predictive markers for breakthrough infections.

Key Insights and Ideas

Consistency Across Immune Status

A primary finding is the remarkable consistency in the relationship between antibody levels and protection across both SARS-CoV-2 naive and non-naive (previously infected) individuals. This suggests that the biological threshold for protection against Omicron is stable regardless of prior infection history.

Peak Response as a Predictor

Antibody levels at the time of the booster (BD1) were found to be poor predictors of subsequent risk. In contrast, the peak levels achieved 28 days post-boost (BD29) were strong correlates of risk. This underscores the importance of the magnitude of the immune response triggered by the booster.

Antibody responses at baseline (BD1) and 28 days post-boost (BD29) for nAbs and IgG bAbs across naive and non-naive groups.

Validation of Surrogate Endpoints

The study provides robust evidence that neutralizing antibody titers continue to serve as a valid surrogate endpoint. This supports the ongoing regulatory strategy of using immunogenicity data to approve variant-specific boosters, bypassing the need for large-scale clinical efficacy trials for every update.

Key Results

The analysis revealed a strong inverse correlation between post-boost antibody levels and the risk of Omicron infection. For naive individuals, every 10-fold increase in nAbs was associated with a 69% reduction in risk (HR = 0.31), while a 10-fold increase in bAbs resulted in an 84% reduction (HR = 0.16). Results for non-naive individuals were nearly identical (72% and 85% reduction for nAbs and bAbs, respectively).

Probability of Omicron COVID-19 infection by 92 days post-boost vs. IgG bAb levels in SARS-CoV-2 naive participants.

Furthermore, booster efficacy was highly dependent on the antibody response. While the overall relative efficacy of the third dose was 46%, participants with high nAb titers (891 AU/ml) experienced 74% efficacy, compared to essentially 0% for those with low titers (56 AU/ml).

Limitations and Future Work

While these findings are significant, they are specific to the BA.1 subvariant. As the virus continues to evolve (e.g., to JN.1), the absolute titers required for protection may change. Additionally, this study did not account for cellular immunity (T-cell and B-cell memory), which is critical for preventing severe disease. Future research should aim to identify "variant-invariant" correlates and standardized units to facilitate comparisons across different strains and vaccine platforms.

Summary updated

Abstract

In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS-CoV-2 Omicron era, Omicron subvariants with varying degrees of immune escape now dominate, seropositivity rates are high, and booster doses are administered, raising questions on whether and how these developments affect the bAb and nAb correlates. To address these questions, we assess post-boost BA.1 Spike-specific bAbs and nAbs as CoRs and as correlates of booster efficacy in COVE. For naive individuals, bAbs and nAbs inversely correlate with Omicron COVID-19: hazard ratios (HR) per 10-fold marker increase (95% confidence interval) are 0.16 (0.03, 0.79) and 0.31 (0.10, 0.96), respectively. In non-naive individuals the analogous results are similar: 0.15 (0.04, 0.63) and 0.28 (0.07, 1.08). For naive individuals, three vs two-dose booster efficacy correlates with predicted nAb titer at exposure, with estimates -8% (-126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), at 56, 251, and 891 Arbitrary Units/ml. These results support the continued use of antibody as a surrogate endpoint.
BibTeX
@inproceedings{zhang2024omicron,
  author = {Bo Zhang and Youyi Fong and Jonathan Fintzi and Eric Chun‐Pu Chu and Holly Janes and Avi Kenny and Marco Carone and David Benkeser and Lars W. P. van der Laan and Weiping Deng and Haiyu Zhou and Xiaowei Wang and Yiwen Lu and Chenchen Yu and Bhavesh Borate and Haiyan Chen and Isabel Reeder and Lindsay N. Carpp and Christopher R. Houchens and Karen Martins and Lakshmi Jayashankar and Chuong Huynh and Carl J. Fichtenbaum and Spyros A. Kalams and Cynthia L. Gay and Michele P. Andrasik and James G. Kublin and Lawrence Corey and Kathleen M. Neuzil and Frances Priddy and Rituparna Das and Bethany Girard and Hana M. El Sahly and Lindsey R. Baden and Thomas Jones and Rubén O. Donis and Richard A. Koup and Peter B. Gilbert and Dean Follmann and On behalf of the United States Government (USG) COVID-19 Immune Assays Team and Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team and USG/CoVPN Biostatistics Team and Lars W. P. van der Laan},
  title = {{Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-52348-9},
}
Figure